Synthesis and antitumor activity of peptide-paclitaxel conjugates

dc.contributor.authorPapas, S.en
dc.contributor.authorAkoumianaki, T.en
dc.contributor.authorKalogiros, C.en
dc.contributor.authorHadjiarapoglou, L.en
dc.contributor.authorTheodoropoulos, P. A.en
dc.contributor.authorTsikaris, V.en
dc.date.accessioned2015-11-24T16:48:52Z
dc.date.available2015-11-24T16:48:52Z
dc.identifier.issn1075-2617-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/9384
dc.rightsDefault Licence-
dc.subjectartificial carriersen
dc.subjectpaclitaxel antitumor agentsen
dc.subjectpaclitaxel derivativesen
dc.subjectpaclitaxel esi-msen
dc.subjecttaxol derivativesen
dc.subjectthioether bonden
dc.subjectside-chainen
dc.subjectbiological-activityen
dc.subjectantigenic peptidesen
dc.subjecthela-cellsen
dc.subjecttaxolen
dc.subjectdeliveryen
dc.subjectproteinsen
dc.subjectprodrugsen
dc.subjectdesignen
dc.subjectagentsen
dc.titleSynthesis and antitumor activity of peptide-paclitaxel conjugatesen
heal.abstractPaclitaxel (Pac) is the most important anticancer drug used mainly in treatment of breast, lung, and ovarian cancer and is being investigated for use as a single agent for treatment of lung cancer, advanced head and neck cancers, and adenocarcinomas of the upper gastrointestinal tract. In this work, we present the synthesis of five 2'-paclitaxel-substituted analogs in which paclitaxel was covalently bound to peptides or as multiple copies to synthetic carriers. Ac-Cys(CH2CO-2'Pac)-Arg-Gly-Asp-Arg-NH2, Folyl-Cys(CH2CO-2'-Pac)-Arg-Gly-Asp-Ser-NH2, Ac-[Lys-Aib-Cys(CH2CO-2'-Pac))(2)-NH2, Ac-[Lys-Aib-Cys(CH2CO-2'-Pac)](3)-NH2 and Ac-[Lys-Aib-Cys(CH2CO-2'-Pac))(4)-NH2 were synthesized using 2'-halogeno-acetylated paclitaxel derivatives. Paclitaxel conjugates showed greater solubility in water than paclitaxel and inhibited the proliferation of human breast, prostate, and cervical cancer cell lines. Although all synthesized compounds had an antiproliferative activity, the Ac[Lys-Aib-Cys(CH2CO-2'-Pac)](4)-NH2 derivative showed improved biological activity in comparison with paclitaxel in cervical and prostate human cancer cells. Copyright (C) 2007 European Peptide Society and John Wiley & Sons, Ltd.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primaryDoi 10.1002/Psc.899-
heal.identifier.secondary<Go to ISI>://000250348600006-
heal.identifier.secondaryhttp://onlinelibrary.wiley.com/store/10.1002/psc.899/asset/899_ftp.pdf?v=1&t=h0f8qcei&s=9ee86cec45701e51c96754d8ac31ca2868641861-
heal.journalNameJournal of Peptide Scienceen
heal.journalTypepeer reviewed-
heal.languageen-
heal.publicationDate2007-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Θετικών Επιστημών. Τμήμα Χημείαςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Φόρτωση...
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή: